Older Adult Training Study With Creatine and CLA

Sarcopenia Clinical Trial

— OTR  

Official title:

Creatine Monohydrate and Conjugated Linoleic Acid Improve Strength and Body Composition Following Resistance Exercise in Older Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00473902
• Other study ID #: Older Adult Training Study
• Status: Completed
• Phase: N/A
• First received: May 15, 2007
• Last updated: May 15, 2007
• Start date: August 2003
• Est. completion date: September 2004

Study information

• Verified date: May 2007
• Source: McMaster University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

We examined whether creatine monohydrate (CrM) and conjugated linoleic acid (CLA) could enhance strength gains and improve body composition (i.e., increase fat-free mass (FFM); decrease body fat) following resistance exercise training in older adults (> 65 y). Our study hypothesized that administering CrM and CLA would yield greater strength and body composition benefits than the placebo group over the six months of resistance exercise

Description:

Men (N=19) and women (N=20) completed six months of resistance exercise training with Creatine Monohydrate (5g/d) + Conjugated Linoleic Acid (6g/d) or placebo with randomized, double-blind, allocation.Outcomes included; strength and muscular endurance, functional tasks, body composition (DEXA scan), blood tests (lipids, liver function, CK, glucose, systemic inflammation markers (IL-6, C-reactive protein)), urinary markers of compliance (creatine/creatinine), oxidative stress (8-OH-2dG, 8-isoP) and bone resorption (Ν-telopeptides).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 39
• Est. completion date: September 2004
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 65 Years to 85 Years

Eligibility

Inclusion Criteria:

• Healthy,

• Ambulatory,

• Recreationally active,

• Community dwelling

Exclusion Criteria:

• Evidence of coronary heart disease;

• Congestive heart disease;

• Uncontrolled hypertension;

• Chronic obstructive pulmonary disease;

• Diabetes mellitus;

• Renal failure;

• Major orthopedic disability; and

• Smoking

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Sarcopenia

Intervention

Behavioral:
• Training

Drug:
• Creatine Monohydrate, Conjugated Linoleic Acid

Locations

Country	Name	City	State
Canada	McMaster University Medical Center	Hamilton	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Hamilton Health Sciences Corporation

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	a. Muscle and bone mass b. Knee extension strength e. Creatine content f. Muscle oxidative capacity g. Aerobic power (oxygen consumption)		six months
Secondary	a. Functional capacity b. Strength with weight machines		six months